new glp 1 receptor agonists Frontiers GLP-1 Receptor Agonists as Treatments

Ovarian stimulation commenced within 5 days of the menstrual cycle using a combination of recombinant follicle-stimulating hormone and recombinant luteinizing hormone (Pergoveris, Merck Serono SA, Aubonne, Switzerland)

UA, recognized as an antioxidant, can neutralize free radicals and reduce their harmful effects on cells

Moreover, it comes in capsule form, allowing accurate dosing and easy handling in laboratory research

According to the findings of animal and human studies, riboflavin status appears to have an effect on the oxidative state of the body, in particular, on lipid peroxidation

is supported by the NUHS Internal Grant Funding under NUS Start-up grant NUHSRO/2022/047/Startup/11, an MOE Tier 2 grant T2EP30124-0014, and a Vidi grant from the Netherlands Organization for Scientific Research (NWO